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ABSTRACT
Objective Survival gains in teenagers and young adults 
(TYA) are reported to be lower than children and adults 
for some cancers. Place of care is implicated, influencing 
access to specialist TYA professionals and research.
Consequently, age- appropriate specialist cancer care 
is advocated for TYA although systematic investigation 
of associated outcomes is lacking. In England, age- 
appropriate care is delivered through 13 Principal 
Treatment Centres (TYA- PTC). BRIGHTLIGHT is the national 
evaluation of TYA cancer services to examine outcomes 
associated with differing places and levels of care. We 
aimed to examine the association between exposure to 
TYA- PTC care, survival and documentation of clinical 
processes of care.
Design Prospective cohort study.
Setting 109 National Health Service (NHS) hospitals 
across England.
Participants 1114 TYA, aged 13–24, newly diagnosed 
with cancer between 2012 and 2014.
Intervention Participants were assigned a TYA- PTC 
category dependent on the proportion of care delivered 
in a TYA- PTC in the first year after diagnosis: all care in 
a TYA- PTC (ALL- TYA- PTC, n=270), no care in a TYA- PTC 
(NO- TYA- PTC, n=359), and some care in a TYA- PTC with 
additional care in a children’s/adult unit (SOME- TYA- PTC, 
n=419).
Primary outcome Data were collected on documented 
processes indicative of age- appropriate care using 
clinical report forms, and survival through linkage to NHS 
databases.
Results TYA receiving NO- TYA- PTC care were less 
likely to have documentation of molecular diagnosis, be 
reviewed by a children’s or TYA multidisciplinary team, be 
assessed by supportive care services or have a fertility 
discussion. There was no significant difference in survival 
according to category of care. There was weak evidence 
that the association between care category and survival 
differed by age (p=0.08) with higher HRs for those over 19 
receiving ALL or SOME- TYA- PTC compared with NO- TYA- 
PTC.
Conclusion TYA- PTC care was associated with better 
documentation of clinical processes associated with age- 
appropriate care but not improved survival.
INTRODUCTION
Cancer in teenagers and young adults (TYA) 
aged 15–24 years is rare, comprising approx-
imately 1% of the total cancer population in 
the UK.1 Historically when compared with chil-
dren and older adults, TYA with cancer have 
experienced lower survival improvements for 
certain cancers. Prolonged pathways to cancer 
diagnosis, less research, an inadequate under-
standing of cancer biology in young people, 
poor choice of treatment protocols and place 
of care are all implicated.2–7 It is now gener-
ally accepted that neither children’s nor adult 
cancer services may fully meet the needs of 
young people with cancer who characteristi-
cally present with a spectrum of rare cancer 
types requiring specialist site specific exper-
tise and additional psychological, educational 
and social support.8–11
TYA cancer care is increasingly recognised 
as an essential specialism. In England, the 
Strengths and limitations of this study
 ► Our study is the first prospective longitudinal nation-
al evaluation of specialist cancer care for teenagers 
and young adults with cancer.
 ► Using routinely collected National Health Service 
(NHS) data, we were able to assign participants into 
three groups according to how much exposure to 
specialist care they had received in the first year 
following diagnosis.
 ► Multiple data sources from patients, NHS and clin-
ical report forms allowed us to adjust for multiple 
predefined confounding variables.
 ► Specialist services for teenagers and young adults 
have evolved since recruitment and may not reflect 
current service configuration.
 ► Our study did not meet its anticipated recruitment 
target, recruiting 20% of the total population diag-
nosed during the recruitment period and this may 
limit generalisability of the results.
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National Institute for Health and Clinical Excellence 
(NICE) published Improving Outcome Guidance for Chil-
dren and Young People with Cancer in 2005, which provided 
details on how care should be delivered to TYA.12 Central 
to this guidance was the establishment of specialist TYA 
Principal Treatment Centres (TYA- PTC) and a mandate 
that young people aged 15–18 years must receive care 
in a TYA- PTC and those aged 19–24 years should have 
unhindered access to age- appropriate care but could chose 
to have care more locally to home in an adult cancer unit. 
Where care is delivered influences clinical outcomes and 
centralisation of care for rare cancers is advocated. Treat-
ment of cancer in children in a limited number of UK 
centres since the 1960s contributed to improvements in 
survival.13 14 For young people, place of care will influence 
access to clinical trials, treatment protocol (paediatric vs 
adult regimens) and access to a wider team specialising 
in TYA care, all of which could influence outcomes. In 
England, young people have free access to healthcare 
and can receive all of their care in a TYA- PTC, or all of 
their care in a children’s or adult cancer unit, or they 
can receive care between these institutions having some 
care delivered in the TYA- PTC with additional compo-
nents being delivered by children’s/adults services. The 
decision- making behind referral into a TYA- PTC or a chil-
dren’s/adult unit is not fully understood and is likely to 
be influenced by local pathways and by older TYA being 
offered a choice.
Despite a lack of evidence, it has been assumed by 
professionals and young people themselves that age- 
appropriate care delivered in a specialist environment 
will positively impact outcomes. Age- appropriate services 
usually include access to a specialist environment, referral 
to specialist TYA multidisciplinary team (MDT) meetings 
in addition to a cancer- site specific MDT, consideration of 
clinical trial accrual, provision of age- appropriate infor-
mation, opportunities to preserve fertility and referral to 
support services such as a TYA clinical nurse specialist, 
psychologist, social worker or youth support coordinator. 
The components of this service that influence outcomes 
are not fully described, although increasingly specialist 
TYA metrics and potential associated outcomes are being 
proposed.15–17 Associated outcomes are thought to include 
survival, quality of life, patient- reported outcomes, long- 
term effects, psychological and social outcomes.
BRIGHTLIGHT was a National Institute for Health 
Research funded programme of research with an over-
arching research question: ‘Do Specialist Services for 
Teenagers and Young Adults with Cancer Add Value?’.18 19 
Specifically, it aimed to describe: what was age- appropriate 
care; what were the key components of such a service; 
what outcomes were impacted; and how much did it cost 
the National Health Service (NHS), young people and 
their families. Central to this programme was a cohort of 
young people aged 13–24 years at cancer diagnosis who 
were recruited within 4 months of a new cancer diagnosis 
and followed for 3 years: the BRIGHTLIGHT cohort.18 We 
previously reported that survival of the BRIGHTLIGHT 
cohort was lower than the population diagnosed over the 
same time period but not recruited to the cohort, which 
was unrelated to cancer type.18 We surmised that survival 
differences between the cohort and the non- recruited 
population may be related to the recruitment window of 
4 months and therefore young people who were sicker 
had more contact with their treatment team and more 
opportunities for recruitment. The aim of this study was 
to determine whether there was any evidence of a causal 
association between the amount of care received in a TYA- 




This paper reports results from several data sources: the 
longitudinal cohort study within BRIGHTLIGHT, a mixed 
methods programme of research, which obtained data 
from young people through a bespoke survey,18 clinical 
report data completed by healthcare professionals and 
Demographic Batch Service data from NHS Digital.18 The 
location of inpatient care for each participant was iden-
tified using routinely collected NHS Hospital Episodes 
Statistics (HES) data. We then developed a bespoke scale 
to assign each participant a category of care; see Taylor et 
al for detail.18 Young people were assigned to a category 
dependent on the proportion of admitted patient care 
delivered in a TYA- PTC in the first 12 months after diag-
nosis: all care delivered in a TYA- PTC (ALL- TYA- PTC), no 
care in a TYA- PTC (NO- TYA- PTC) and some care deliv-
ered in a TYA- PTC with additional care in a children’s or 
adult cancer unit (SOME- TYA- PTC). Sample size calcula-
tions were based on the primary outcome measure of the 
cohort, quality of life.18
Participants and setting
The BRIGHTLIGHT cohort comprised young people 
aged 13–24 years, newly diagnosed with cancer (Classifi-
cation of Disease ICD-10 codes C00- C97) in an English 
hospital and recruited within 4 months of diagnosis. Eligi-
bility criteria were as inclusive as possible so no restriction 
according to language or any sensory impairment that 
affected communication was applied. The only exclu-
sion criteria were: young people receiving a custodial 
sentence; if the young person was not anticipated to be 
alive at the first point of data collection (6 months after 
diagnosis); recurrence of a previous cancer or they were 
not capable of completing a survey, for example, sedated 
or in intensive care. The processes for recruitment are 
reported in detail elsewhere.18 20 21 BRIGHTLIGHT was 
open to recruitment in 109 NHS hospitals in England, of 
whom 97 hospitals recruited at least one young person. 
Young people were recruited between October 2012 and 
April 2015 (diagnosed between July 2012 and December 
2014). They gave written consent (parent consent also 
obtained from those less than 16 years); the study was 
 on A









pen: first published as 10.1136/bm





3Fern LA, et al. BMJ Open 2021;11:e044854. doi:10.1136/bmjopen-2020-044854
Open access
approved by London- Bloomsbury NHS Research Ethics 
Committee and the Confidentiality Advisory Group.
Data collection
We assessed documentation of the following clinical 
processes:
 ► Histological diagnosis.
 ► Molecular confirmation of diagnosis (where relevant).
 ► Cancer stage or prognostic group defined (for 
leukaemia, total white blood cell count).
 ► Initial treatment plan.
 ► Treatment protocol for systemic therapy and/or for 
radiotherapy (RT).
 ► Evidence of MDT communication including chil-
dren’s, TYA or site- specific.
 ► Assessment by supportive care services based on 
evidence in notes of contact with a clinical nurse 
specialist plus one other member of the MDT (social 
worker, youth support coordinator, counsellor, 
psychologist, dietician, physiotherapist, occupational 
therapist).
 ► A record of fertility being discussed.
 ► A record of consideration for inclusion in a clinical 
trial.
Survival data were obtained from the Demographic 
Batch Service at NHS Digital reported up until October 
2018.
To describe patient prognosis at recruitment, an existing 
scoring system was identified that uses anticipated 5- year 
survival to form groups of patients with expected survival 
of greater than 80%, 50%–80% and less than 50%.22 To 
measure severity of illness, we developed a bespoke scale 
which accounts for the range of cancer types, staging 
systems, symptom burden, treatment burden, potential 
late effects and prognosis. This classifies patients as ‘least 
severe’, ‘intermediate’ and ‘most severe’ based on their 
cancer- specific information.18
Analysis
Analysis was based on a predefined analysis plan using 
STATA V.15. For each clinical process outcome, the 
proportion of patients where the item was found to be 
documented in clinical records was reported by category 
of care. Proportions were compared across groups using 
χ2 tests (including a trend test).
Survival time for each participant was calculated from 
date of diagnosis to date of death or censored at the date 
last known to be alive up to 29 October 2018. Kaplan- 
Meier survival curves were plotted for each category of 
care (NO- TYA- PTC, SOME- TYA- PTC and ALL- TYA- PTC) 
and estimates of cumulative survival at 1–4 years (with 
95% CIs) were calculated. The relationship between 
survival time and TYA category was investigated using a 
Cox regression model adjusted for confounding factors 
identified using a causal inference approach and based 
on the conceptual model underpinning the BRIGHT-
LIGHT Survey19 in the form of a Directed Acyclic Graph 
(DAG) (online supplemental file; DAGitty software www. 
dagitty. net). Factors adjusted for were age at diagnosis, 
sex, type of cancer (leukaemia, lymphoma, brain and 
central nervous system (CNS), bone tumours, sarcoma, 
germ cell, melanoma, carcinomas, other), socioeconomic 
status (Index of Multiple Deprivation rank23), severity of 
cancer (least, intermediate, most18), ethnicity (white, 
other), days in hospital over 12 months since diagnosis, 
treatment received in 12 months since diagnosis (systemic 
anticancer therapy (SACT) only, RT only, Surgery only, 
Surgery and SACT/SACT and RT and Surgery/RT and 
SACT/Surgery and RT/Transplant, Other). Geograph-
ical region of treatment (North East, North West, York-
shire, East Midlands, West Midlands, London, South East 
and South West) was included in the model as a random 
effect (frailty term). The proportional hazards assump-
tions of the Cox regression model were checked. Models 
were extended to include interaction terms to investigate 
whether the association between TYA group and survival 
was different by age at diagnosis (using categories of 
13–18 and 19–24 years, and age in years) and tumour type 
(using categories, haematology and oncology).
RESULTS
A total of 5953 incident cases were recorded in England, 
of which 5835 were eligible to participate and 1126 young 
people were recruited to the cohort (19.3%). Valid 
consent was available for 1114. Participation at each wave 
of data collection has been previously described.18 Partic-
ipant characteristics are shown in table 1. In comparison 
to TYA diagnosed in the same period but not recruited 
to the cohort, there was under- representation of patients 
with carcinoma, CNS cancers and melanoma, and over- 
representation of patients with leukaemia, lymphoma, 
germ cell tumours and bone tumours.18 Two diagnostic 
groups accounted for 50% of the cohort, (lymphoma 
31% and germ cell 19%).
Overall, 359 (34.3%) patients were in the NO- TYA- PTC 
group, 415 (39.8%) in the SOME- TYA- PTC group and 
270 (25.9%) in the ALL- TYA- PTC. Cancer type varied by 
category of care, lymphoma was the most common in all 
groups (38%, 24%, 36%, NO, SOME, ALL, respectively). 
Leukaemia (20%) was the second most common cancer 
in the ALL- TYA- PTC, bone (22%) in the SOME- TYA- PTC 
and germ cell (20%) in the NO- TYA- PTC. There was 
variability in the distribution of prognosis and severity of 
illness scores between categories of care, the NO- TYA- PTC 
having the highest proportion of ‘least severe disease’ 
70%, compared with 43% in the SOME- TYA- PTC and 49% 
in the ALL- TYA- PTC. The SOME- TYA- PTC had highest 
proportion of most severe disease, 33% compared with 
11% and 22% in the NO and ALL groups, respectively. 
The NO- TYA- PTC group was also older (table 1).
The number of days in hospital over the 12 months since 
diagnosis varied between groups. For the NO- TYA- PTC 
group, the total number of days ranged from 1 to 213 
(median 13, IQR, 4–27), for the SOME- TYA- PTC care 
group, total days ranged from 2 to 228 (median 59, 
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Table 1 BRIGHTLIGHT cohort characteristics by level of teenagers and young adults (TYA) care category at 12 months from 
diagnosis
Characteristic







Age at diagnosis (years)
  Mean (SD) 21.11 (3.04) 19.44 (3.36) 19.74 (3.23)
Gender
  Male 193 (54%) 224 (54%) 156 (58%)
  Female 166 (46%) 191 (46%) 114 (42%)
Ethnicity* N=351 N=408 N=259
  White 312 (89%) 344 (84%) 221 (85%)
  Mixed 9 (3%) 9 (2%) 6 (2%)
  Asian 18 (5%) 36 (9%) 25 (10%)
  Black 7 (2%) 11 (3%) 2 (1%)
  Chinese 0 1 (<1%) 2 (1%)
  Other 5 (1%) 7 (2%) 3 (1%)
Socioeconomic status (IMD quintile) N=354 N=404 N=263
  1—most deprived 85 (24%) 100 (25%) 51 (20%)
  2 67 (19%) 68 (17%) 48 (18%)
  3 66 (19%) 83 (21%) 51 (19%)
  4 83 (23%) 77 (19%) 49 (19%)
  5—least deprived 53 (15%) 76 (19%) 64 (24%)
Marital status N=250 N=262 N=172
  Married/civil partnership 9 (4%) 8 (3%) 6 (3%)
  Cohabiting 43 (17%) 27 (10%) 18 (10%)
  Single/divorced 198 (80%) 227 (87%) 148 (86%)
Current status N=277 N=312 N=193
  Working full/part time 126 (45%) 72 (23%) 43 (22%)
  In education 61 (22%) 112 (36%) 81 (42%)
  Other work (apprentice/intern/voluntary) 6 (2%) 5 (2%) 6 (3%)
  Unemployed 10 (4%) 11 (4%) 7 (4%)
  Long- term sick 39 (14%) 51 (16%) 31 (16%)
  Not seeking work 35 (13%) 61 (19%) 25 (13%)
  Type of cancer1
  Leukaemia 27 (8%) 59 (14%) 53 (20%)
  Lymphoma 138 (38%) 100 (24%) 96 (36%)
  CNS 12 (3%) 13 (3%) 17 (6%)
  Bone 10 (3%) 93 (22%) 9 (3%)
  Sarcomas 10 (3%) 30 (7%) 14 (5%)
  Germ cell 71 (20%) 75 (18%) 46 (17%)
  Skin 34 (9%) 1 (<1%) 6 (2%)
  Carcinomas (not skin) 51 (14%) 41 (10%) 27 (10%)
  Miscellaneous specified† 5 (1%) 3 (<1%) 1 (<1%)
  Unspecified malignant 1 (<1%) 0 1 (<1%)
Severity of illness18
  Least 251 (70%) 180 (43%) 131 (49%)
Continued
 on A
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Characteristic







  Intermediate 67 (19%) 99 (24%) 80 (30%)
  Most 41 (11%) 136 (33%) 59 (22%)
Prognostic score23 N=354 N=413 N=270
  <50% 30 (8%) 76 (18%) 61 (23%)
  50%–80% 70 (20%) 166 (40%) 65 (24%)
  >80% 254 (72%) 171 (41%) 144 (53%)
City‡ N=359 N=415 N=270
  Birmingham 54 (15%) 75 (18%) 18 (7%)
  Bristol 65 (18%) 39 (9%) 8 (3%)
  Cambridge 13 (4%) 8 (2%) 2 (1%)
  Manchester 32 (9%) 44 (11%) 20 (7%)
  Merseyside 15 (4%) 13 (3%) 11 (4%)
  East Midlands 19 (5%) 34 (8%) 73 (27%)
  Leeds 24 (7%) 38 (9%) 39 (14%)
  Newcastle 15 (4%) 9 (2%) 33 (12%)
  Oxford 6 (2%) 5 (1%) 8 (3%)
  London 84 (23%) 116 (28%) 14 (5%)
  Sheffield 8 (2%) 13 (3%) 13 (5%)
  Southampton 24 (7%) 21 (5%) 31 (11%)
Region‡ N=359 N=415 N=270
  North East 15 (4%) 9 (2%) 33 (12%)
  North West 47 (13%) 57 (14%) 31 (11%)
  Yorkshire 32 (9%) 51 (12%) 52 (19%)
  East Midlands 19 (5%) 34 (8%) 73 (27%)
  West Midlands 54 (15%) 75 (18%) 18 (7%)
  London 84 (23%) 116 (28%) 14 (5%)
  South East 43 (12%) 34 (8%) 41 (15%)
  South West 65 (18%) 39 (9%) 8 (3%)
Treatment received in the first 12 months since 
diagnosis
  SACT only 111 (31%) 114 (27%) 119 (44%)
  Surgery and SACT 55 (15%) 132 (32%) 49 (18%)
  Surgery only 92 (26%) 20 (5%) 23 (9%)
  SACT and RT 49 (14%) 61 (15%) 30 (11%)
  Surgery, RT and SACT 12 (3%) 60 (15%) 24 (9%)
  Surgery and RT 17 (5%) 9 (2%) 16 (6%)
  Transplant 9 (3%) 12 (3%) 7 (3%)
  RT only 7 (2%) 5 (1%) 1 (<1%)
  Other 7 (2%) 2 (<1%) 1 (<1%)
Total days in hospital over 12 months
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IQR 20–103) and for the ALL- TYA- PTC group the total 
number of days ranged from 1 to 286 (median 29, IQR 
11–73).
Processes of care
Clinical records were available for 1078 young people 
of which 1009 were assigned to: NO- TYA- PTC (n=333); 
SOME- TYA- PTC (n=409) and ALL- TYA- PTC (n=267). 
HES data were not available for 69 young people so they 
could not be assigned a category. The comparison of 
processes of care according to category of care is shown 
in table 2. There was no evidence of a difference between 
the three groups for the documentation of: histolog-
ical diagnosis, cancer stage or prognosis, consideration 
for entry into a clinical trial and discussion at an MDT. 
Those receiving NO- TYA- PTC were more likely to have 
documented discussion in a site- specific MDT but had 
the lowest proportion with documented discussion in a 
TYA MDT and children’s MDT. There was no significant 
difference between documentation of an initial treat-
ment plan but there was a trend that this was more likely 
to have been recorded with more TYA- PTC care. Young 
people in NO- TYA- PTC had less frequent documentation 
of a molecular diagnosis (where molecular analysis was 
appropriate), discussions about fertility and assessments 
by supportive care services defined as contact with a clin-
ical nurse specialist and one other professional such as 
youth support coordinator, social worker, psychologist 
(see methods for complete list).
Survival
The duration of follow- up by October 2018 is shown in 
table 3. The number of deaths in the NO- TYA- PTC group 
was 27 (8%), compared with 35 (13%) in ALL- TYA- PTC 
and 91 (22%) in SOME- TYA- PTC. The cumulative proba-
bility of survival by time since diagnosis for the TYA- PTC 
categories is shown in figure 1 and table 4. Although 
survival probabilities at 1 year were similar, there was 
clear divergence between the groups over the following 
time period, such that probabilities were highest for those 
receiving NO- TYA- PTC, followed by ALL- TYA- PTC care, 
then SOME- TYA- PTC care. Following full adjustment for 
confounding factors, regression (table 5) showed there 
was no evidence of a relationship between the category of 
care and hazard (risk) of death.
Subgroup analyses showed no statistical evidence that 
the relationship between survival and level of care was 
different for the combined group of leukaemia and 
lymphomas compared with other cancers (table 6). There 
was however weak evidence of a difference in the effect of 
level of care on survival by age group, notably with lower 
risk of death when comparing SOME- TYA- PTC and ALL- 
TYA- PTC with NO- TYA- PTC in those aged under 19 years 
at diagnosis, while these relative risks were higher in the 
over 19 group. A similar pattern was seen when consid-
ering age as continuous.
Characteristic







  Yes 121 (42%) 86 (24%) 48 (21%)
  No (or <19 years) 167 (58%) 270 (76%) 185 (79%)
Long- term condition prior to cancer? N=277 N=311 N=193
  Yes 20 (7%) 34 (11%) 18 (9%)
  No 257 (93%) 277 (89%) 175 (91%)
Time to diagnosis: days from first symptom N=264 N=304 N=188






Time to diagnosis: number of GP visits before 
diagnosis
N=274 N=311 N=193






Values are frequency (%) unless stated otherwise.
*Wave 1 data were used with missing values completed using available Public Health England data.
†Includes 4 ‘unclassified’—treated in cancer unit but did not have cancer.
‡Where available based on hospital of diagnosis, for 77 cases based on recruiting hospital. Note: Manchester=Christie, 
Merseyside=Clatterbridge, London=the Royal Marsden Hospital/University College London Hospitals.
§Those <19 at diagnosis were assumed not to have been given a choice.
CNS, central nervous system; GP, general practitioner; IMD, Index of Multiple Deprivation; PTC, Principal Treatment Centres; RT, radiotherapy; 
SACT, systemic anticancer therapy.
Table 1 Continued
 on A
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DISCUSSION
We have reported on a national longitudinal evalua-
tion of specialist cancer services for young people aged 
13–24 years at diagnosis defining the TYA- PTCs and 
their networks as they were described in the UK NICE 
Improving Outcomes Guidance in 2005.12 We used 
routinely collected NHS data (HES) which records 
hospital admission data to measure how much care young 
people received in the TYA- PTC, dividing our cohort into 
three distinct groups, all care delivered in a TYA- PTC 
(ALL- TYA- PTC) no care in a TYA- PTC (NO- TYA- PTC) 
and those who received some care in the TYA- PTC and 
other parts of their care in another children’s or adult 
hospital. We assessed documentation of clinical processes 











N Yes No N Yes No N Yes No




186 49 (26%) 137 (74%) 304 106 (35%) 198 (65%) 200 87 (44%) 113 (56%) 0.002
0.02
Cancer stage or 
prognostic group†
333 311 (93%) 22 (7%) 409 383 (94%) 26 (6%) 267 253 (95%) 14 (5%) 0.77
0.50




331 321 (97%) 10 (3%) 408 392 (96%) 16 (4%) 267 259 (97%) 8 (3%) 0.73
0.97
Children’s MDT 329 34 (10%) 295 (90%) 403 81 (20%) 322 (80%) 265 58 (22%) 207 (78%) <0.001
<0.001
TYA MDT 326 164 (50%) 162 (50% 401 285 (71%) 116 (29%) 265 207 (78%) 58 (22%) <0.001
<0.001





















328 207 (63%) 121 (37%) 405 252 (62%) 153 (38%) 256 176 (69%) 80 (31%) 0.21
0.19
From case report form data: completed/partially completed=1078; 1009 have category of specialist care recorded.
*indicated as ‘not relevant’ for: NO- teenage and young adult (TYA)- Principal Treatment Centres (PTC), n=137; SOME- TYA- PTC, n=97; ALL- 
TYA- PTC, n=65.
†Cancer stage or prognostic group documented is defined as: for leukaemia—a white blood cell count measure is provided; for lymphoma 
if stage (1–4) is entered (variable ‘stage’); for solid tumour use variable ‘has the tumour been staged?’ If these things are not recorded for the 
appropriate cancer type, then coded as not documented. Cancer type is determined by birch classification.
MDT, multidisciplinary team.

















PTC, Principal Treatment Centres; TYA, teenagers and young adults.
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assumed to be related to quality of care and found those 
receiving NO- TYA- PTC were less likely to have a record 
of molecular diagnosis (where relevant). Additionally, 
this group were less likely to have documentation of 
review by a children’s or TYA MDT, have an assessment 
by supportive care services or have a fertility discussion 
compared with those treated in SOME- TYA- PTC or ALL- 
TYA- PTC. These are criteria which we would expect to 
be associated with specialist age- appropriate care16 17; 
therefore, it is not surprising these appear to be more 
frequently documented in the ALL and SOME group.
Our results suggest differences between the groups in 
these measures of the quality of cancer care delivered 
to young people. However, this did not appear to have 
an impact on survival outcomes. One- year survival was 
similar between the groups; at 4 years, survival was highest 
in the NO- TYA- PTC group, followed by ALL- TYA- PTC 
and lowest in the SOME- TYA- PTC group. However, this 
was not significant. One of the reasons for implementing 
a new model of care in 2005 specific for TYA with cancer 
was due to the disparity in survival compared with chil-
dren and older adults.12 It is therefore disappointing 
that there were no survival differences noted between 
the three categories. Alternatively, we could view this as 
a positive finding—wherever young people choose to be 
treated, their survival outcomes are the same. The work 
we did with young people to develop BRIGHTLIGHT 
highlighted that they did not perceive survival alone as 
the most import outcome. Quality of life and the ability 
to get back on with life were as important.18 19 While we 
have shown a better improvement in quality of life when 
treated in a TYA- PTC,23 we have yet to ascertain whether 
young people’s reintegration into life when treatment 
ends is also better.
There was weak evidence that increasing age was 
associated with higher risk of death for those in the 
SOME- TYA- PTC compared with NO- TYA- PTC and ALL- 
TYA- PTC, an important finding given that it is this group 
who have a choice over where to receive their care.12 We 
believe that further investigation into the lower survival in 
the SOME- TYA- PTC group is warranted, particularly the 
association with age. Those aged over 19 years at diag-
nosis had the more pronounced effects in the subgroup 
analysis, but the direction of the effect differed substan-
tially for under 19s compared with the overall effect.
There is a paucity of existing literature to compare our 
results with and comparisons are further confounded 
by variation in healthcare systems, distinct models of 
specialist age- appropriate care adopted and the interna-
tional definition of TYA which can extend up to 39 years 
in some countries.24 A previous retrospective regional 
study of children and TYA in England found a survival 
benefit of being treated in a PTC for poor prognosis 
leukaemia and a converse relationship for those with 
soft tissue sarcoma, no significant differences in survival 
were observed for those with lymphoma, CNS, bone and 
germ cell tumours.25 Of note, a previous study has also 
shown those receiving ‘SOME’ specialist care have poorer 
survival for some indications (Birch 2013, unpublished 
thesis). These studies suggest that some tumour groups 
may benefit from care at the PTC however, due to our 
previously reported difficulties with recruitment and 
reduction in sample size20 we were unable to conduct the 
detailed analysis of individual cancer types as planned, 
and thus benefits of the PTC may be masked within the 
grouping of ‘haematology’ and ‘solid tumours’.
Limitations
Despite our study including a large, broadly repre-
sentative sample of newly diagnosed TYA with cancer 
followed- up for 3 years, and our analyses being adjusted 
for factors known to affect outcomes in cancer there are 
some limitations to our study. Our definition of ‘specialist’ 
was based on the TYA- PTC care model as defined by the 
NICE Improving Outcomes Guidance issued in 2005,12 
which does not necessarily reflect current delivery 
Figure 1 Comparison of survival according to the three 
categories of care (unadjusted). TYA, teenagers and young 
adults.
Table 4 Estimated cumulative survival probabilities by categories of teenagers and young adults (TYA) care and year from 
diagnosis (95% CI)
NO- TYA- PTC SOME- TYA- PTC ALL- TYA- PTC
1 year 0.98 (0.96 to 0.99) 0.97 (0.95 to 0.99) 0.98 (0.95 to 0.99)
2 years 0.95 (0.92 to 0.97) 0.89 (0.86 to 0.92) 0.93 (0.89 to 0.95)
3 years 0.94 (0.91 to 0.96) 0.83 (0.79 to 0.86) 0.90 (0.85 to 0.93)
4 years 0.93 (0.90 to 0.95) 0.80 (0.76 to 0.84) 0.89 (0.84 to 0.92)
PTC, Principal Treatment Centres.
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of age- appropriate care.9 The study population were 
recruited during a period of evolution of TYA services 
in England; therefore, the models of care are unlikely to 
reflect current practice, particularly as we have identified 
that specialist age- appropriate care takes time to develop 
(Lea 2019 Unpublished thesis).13 Additionally, cate-
gorising TYA- PTC assumes that all PTCs are equal and 
does not measure the quality of care delivered. We know 
national variation exists in configuration and maturity of 
services,26 particularly during 2012–2014 when patients 
were recruited. Further, due to the coding of hospital 
inpatient data it is possible that some patients have been 
misattributed as receiving care in the TYA- PTC when they 
may have been cared for in a Trust which had a TYA- PTC 
but care was delivered at a different hospital and not in 
the TYA unit. An additional limitation of the categorisa-
tion of care was that it was based on previous work (Birch 
2013, unpublished thesis), which only included inpatient 
admission data. Potentially, hospital visits involving treat-
ment as outpatient care were not included. This could 
have resulted in patients been misclassified as ALL- 
TYA- PTC or NO- TYA- PTC.
Consideration must also be given to additional factors 
influencing survival outcomes which we did not collect 
or measure. These include deviation from the intended 
treatment plan such as the proportion of treatment 
Table 5 Results from Cox regression model for survival from diagnosis by categories of teenagers and young adults (TYA) 
care received during the first 12 months from diagnosis
HR 95% CI P value *
Unadjusted model (N=1044)
TYA care category
(vs NO- TYA- PTC)
SOME- TYA- PTC 3.14 2.04 to 4.83 p<0.001
ALL- TYA- PTC 1.79 1.08 to 2.96
Fully adjusted model (N=1000)
TYA care category
(vs NO- TYA- PTC)
SOME- TYA- PTC 1.55 0.94 to 2.58 p=0.15
ALL- TYA- PTC 1.13 0.64 to 1.97
*P value from a likelihood ratio test.
†Adjusted for age at diagnosis, sex, type of cancer, socioeconomic status (Index of Multiple Deprivation rank), severity of cancer, treatment, 
days in hospital, and ethnicity geographical region of treatment were included as a random effect (frailty term).
PTC, Principal Treatment Centres.
Table 6 Planned subgroup investigations for cancer type (leukaemia/lymphoma vs other) and age group (<19 vs 19+): results 
from fully adjusted* models with interaction terms (N=1000)
TYA care category Fully adjusted HR 95% CI
P value from 
interaction
Cancer type     
  Leukaemia/lymphoma SOME- TYA- PTC versus NO- TYA- PTC 1.37 0.63 to 3.01 p=0.95
ALL- TYA- PTC versus NO- TYA- PTC 0.97 0.41 to 2.28
  Other cancers SOME- TYA- PTC versus NO- TYA- PTC 1.34 0.68 to 2.63
ALL- TYA- PTC versus NO- TYA- PTC 1.09 0.52 to 2.27
Age group     
  Age<19 years SOME- TYA- PTC versus NO- TYA- PTC 0.81 0.41 to 1.57 p=0.08
ALL- TYA- PTC versus NO- TYA- PTC 0.79 0.37 to 1.71
  Age 19+years SOME- TYA- PTC versus NO- TYA- PTC 1.75 0.99 to 3.06
ALL- TYA- PTC versus NO- TYA- PTC 1.14 0.59 to 2.23
Continuous age   Coefficient for age 
(per year)
  
  NO- TYA- PTC 0.95 0.85 to 1.06 p=0.07
SOME- TYA- PTC 1.11 1.03 to 1.18
ALL- TYA- PTC 1.05 0.94 to 1.17
Adjusted for age at diagnosis, type of cancer (detailed categories), socioeconomic status (Index of Multiple Deprivation rank), severity of 
cancer, ethnicity (white vs other), gender, treatment (detailed categories) received in 6 months from diagnosis, days in hospital within 12 
months of diagnosis with region as random effect.
PTC, Principal Treatment Centres; TYA, teenagers and young adults.
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delivered, delays/reduction in delivery and toxicity. 
Therefore, it was not possible to determine the dose 
or type of chemotherapy or RT received by patients in 
each group and these would be important determinants 
of survival. Our scale for place of care was derived only 
from inpatient care and not care or treatment delivered 
as an outpatient. Thus, we may have missed considerable 
elements of the care received.
Further to this, overall survival of the BRIGHTLIGHT 
cohort was lower than those diagnosed during the same 
period but not recruited; therefore, our findings may not 
reflect the experience of the whole TYA population.18 We 
also do not know the decision- making processes behind 
referral of patients into each TYA- PTC group at diagnosis, 
it may be that patients with better prognosis are treated 
more locally with site specific expertise competent at 
treating the cancer with good survival outcomes, while 
those with more complex disease and holistic needs are 
referred into the specialist TYA service.
CONCLUSION
We have reported on the first systematic longitudinal eval-
uation of cancer services for young people. Young people 
were more likely to have had documentation of access 
to supportive care services or have a fertility discussion 
if they had some or all of their care delivered by the TYA- 
PTC, which existing literature supports as important for 
TYA.
Overall, survival at 4 years was good across all three 
categories of care with some differences between the 
NONE, ALL and SOME groups as defined by NICE 
improving outcomes service specification in 2005. The 
factors contributing to survival differences between the 
groups warrants further investigation particularly the 
relationship between survival, level of TYA care and age. 
BRIGHTLIGHT results are immediately important for 
current healthcare recommendations for young people 
with cancer in England. The currently proposed model of 
care proposed by NHS England advocates ‘Joint Care’ but 
with an emphasis to increase communication between the 
TYA- PTCs and selected local hospitals. Further enquiry 
is required with additional prospective data collection to 
assess whether this proposed Joint Care would generate a 
similar pattern of survival trends as the ‘SOME- TYA- PTC’ 
group in our study.
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